Breakthrough trial targets deadly pancreatic cancer with new Antibody-Chemo combo
Disease control
Not yet recruiting
This study is testing whether adding a new antibody drug called FG-M108 to standard chemotherapy helps people with advanced pancreatic cancer live longer. It will involve 524 adults whose cancer has a specific protein marker called CLDN18.2 and who haven't had prior treatment for…
Phase: PHASE3 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC